Market Overview

Corbus Pharmaceuticals: Q1 Earnings Insights


Shares of Corbus Pharmaceuticals (NASDAQ:CRBP) fell 1.3% in pre-market trading after the company reported Q1 results.

Quarterly Results

Earnings per share were flat 0.00% year over year to ($0.43), which missed the estimate of ($0.40).

Revenue of $1,762,000 lower by 6.57% from the same period last year, which missed the estimate of $2,410,000.

Looking Ahead

Earnings guidance hasn't been issued by the company for now.

Revenue guidance hasn't been issued by the company for now.

Details Of The Call

Date: May 11, 2020

Time: 08:00 PM ET

Webcast URL:

Price Action

Company's 52-week high was at $7.99

Company's 52-week low was at $3.29

Price action over last quarter: Up 62.16%

Company Description

Corbus Pharmaceuticals Holdings Inc is a Phase 3 clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The company's lead product candidate, lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus.


Related Articles (CRBP)

View Comments and Join the Discussion!

Posted-In: Earnings News